IN2014DN11269A - - Google Patents

Info

Publication number
IN2014DN11269A
IN2014DN11269A IN11269DEN2014A IN2014DN11269A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A IN 11269DEN2014 A IN11269DEN2014 A IN 11269DEN2014A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A
Authority
IN
India
Prior art keywords
cell
malignant cancers
cell malignant
lymphoma
cancers include
Prior art date
Application number
Other languages
English (en)
Inventor
Francesco Bertoni
Paola Bonetti
Original Assignee
Oncoethix Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Sa filed Critical Oncoethix Sa
Publication of IN2014DN11269A publication Critical patent/IN2014DN11269A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN11269DEN2014 2012-06-25 2013-06-25 IN2014DN11269A (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US201261670918P 2012-07-12 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
IN2014DN11269A true IN2014DN11269A (https=) 2015-10-09

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11269DEN2014 IN2014DN11269A (https=) 2012-06-25 2013-06-25

Country Status (12)

Country Link
US (1) US20140018353A1 (https=)
EP (1) EP2863923B1 (https=)
JP (1) JP6265979B2 (https=)
KR (1) KR20150045423A (https=)
CN (1) CN105050605A (https=)
AU (1) AU2013283378B2 (https=)
BR (1) BR112014032105A2 (https=)
CA (1) CA2877434A1 (https=)
IN (1) IN2014DN11269A (https=)
MX (1) MX2014015986A (https=)
RU (1) RU2659171C2 (https=)
WO (1) WO2014001356A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
WO2015014998A1 (en) * 2013-08-01 2015-02-05 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN105960239A (zh) 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
CN107073014A (zh) 2014-05-02 2017-08-18 翁科埃斯克斯有限公司 利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法
JP2017514907A (ja) * 2014-05-02 2017-06-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
CA2947970A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
EP3154549A1 (en) 2014-06-13 2017-04-19 Oncoethix GmbH Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
US9968620B2 (en) 2014-08-19 2018-05-15 Oncoethix Gmbh Methods of treating lymphoma using thienotriazolodiazepine compounds
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP7526721B2 (ja) * 2018-09-11 2024-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 癌治療のためのブロモドメインＢＲＤ４阻害剤としてのｔｅｒｔ－ブチル（Ｓ）－２－（４－（フェニル）－６Ｈ－チエノ［３，２－ｆ］［１，２，４］トリアゾロ［４，３－ａ］［１，４］ジアゼピン－６－イル）アセテート誘導体及び関連化合物
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
DE69717160T2 (de) * 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
PL2902030T3 (pl) * 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Also Published As

Publication number Publication date
CA2877434A1 (en) 2014-01-03
JP2015531747A (ja) 2015-11-05
MX2014015986A (es) 2016-02-11
BR112014032105A2 (pt) 2017-08-01
WO2014001356A1 (en) 2014-01-03
AU2013283378A1 (en) 2015-01-29
CN105050605A (zh) 2015-11-11
KR20150045423A (ko) 2015-04-28
RU2015101106A (ru) 2016-08-10
AU2013283378B2 (en) 2017-07-13
EP2863923B1 (en) 2019-05-08
EP2863923A1 (en) 2015-04-29
RU2659171C2 (ru) 2018-06-28
JP6265979B2 (ja) 2018-01-24
US20140018353A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IN2014DN11269A (https=)
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
MX2013010770A (es) Tratamiento de tumores solidos.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
AU2011328009A8 (en) Compounds and methods for treating pain
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
MX356210B (es) Formulaciones de polimero acrilico.
NZ625440A (en) Anti-cxcr1 compositions and methods
MX2014013090A (es) Derivados de pirrolotriazinona.
MX351149B (es) Derivados biciclicos de pirazinona.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
PH12013501115A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia